Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone
Tue, 15/09/2020 - 00:00
0 min
Download related document
Select rating
Give Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone 1/5
Give Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone 2/5
Give Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone 3/5
Give Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone 4/5
Give Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone 5/5
No votes yet
Related
ROVI achieves second place in a worldwide sustainability rating
ROVI’s ESG aspects have been evaluated by Sustainalytics, a Global Leader in ESG & Corporate Governance, obtaining an “ESG Risk Rating...
1 min
09/08/2021
ROVI achieves an increase of 52% in operating income and 75% in EBITDA
Laboratorios Farmacéuticos Rovi, SA (BME: ROVI), company Pan-European pharmaceutical company specialized and dedicated to the research...
6 min
28/07/2021
First half 2021 results presentation
0 min
28/07/2021
See More
Email
Facebook
Twitter
LinkedIn